Massimo Breccia

Summary

Affiliation: University of Rome La Sapienza
Country: Italy

Publications

  1. ncbi Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leukemia 21:79-83. 2007
  2. ncbi Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy Electronic address
    Leuk Res 37:713-20. 2013
  3. ncbi Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy Electronic address
    Cancer Lett 333:32-5. 2013
  4. ncbi Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Lymphoma 53:2439-43. 2012
  5. ncbi Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Res 37:383-5. 2013
  6. ncbi Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Cancer Lett 325:18-25. 2012
  7. ncbi Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Crit Rev Oncol Hematol 84:93-100. 2012
  8. ncbi 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Lymphoma 53:1558-60. 2012
  9. ncbi Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Ann Hematol 91:1345-9. 2012
  10. ncbi How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Cancer Lett 322:127-32. 2012

Detail Information

Publications112 found, 100 shown here

  1. ncbi Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leukemia 21:79-83. 2007
    ..Our findings suggest that, in APL patients consistent biologic features of leukemia cells may predict increased risk of developing thrombosis...
  2. ncbi Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy Electronic address
    Leuk Res 37:713-20. 2013
    ..Second generation frontline TKIs reduce the incidence of most of side effects reported with imatinib and peculiar events observed are typically manageable through drug dose reduction or treatment interruption...
  3. ncbi Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy Electronic address
    Cancer Lett 333:32-5. 2013
    ..These results suggest that CML patients with increased weight at baseline should be followed and carefully monitored if treated with standard dose imatinib frontline for a possible early switch...
  4. ncbi Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Lymphoma 53:2439-43. 2012
    ..The present results suggest that younger MDS could be identified as a distinct subset. For patients belonging to the low/intermediate-I risk group, due to a low transformation rate, aggressive approaches should rarely be recommended...
  5. ncbi Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Res 37:383-5. 2013
    ..001), with a 5-year CIR of 29.6% compared to 12% (p=0.03). APL patients with delayed CR should be more closely monitored during follow-up for early identification of relapse and prompt administration of pre-emptive salvage therapy...
  6. ncbi Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Cancer Lett 325:18-25. 2012
    ..In this article, we overview studies demonstrating prognostic implications of being suboptimal responders to imatinib as well as results of recent clinical trials testing new generation tyrosine kinase inhibitors in this setting...
  7. ncbi Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Crit Rev Oncol Hematol 84:93-100. 2012
    ..The aim of this review is, through the revision of published data, to highlight the fact that elderly CML patients can benefit from target therapy with limited adverse events...
  8. ncbi 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Lymphoma 53:1558-60. 2012
    ..Our results suggest that advanced age should not preclude effective treatment with azacitidine in non-selected elderly patients wih MDS...
  9. ncbi Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Ann Hematol 91:1345-9. 2012
    ..In conclusion, the oral iron chelator deferasirox is effective and safe when used in MDS patients with transfusion requirement, also if administered concomitantly with other drugs...
  10. ncbi How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Cancer Lett 322:127-32. 2012
    ..At the present time, after FDA approval of both agents in first-line, several points of discussion are still unresolved...
  11. ncbi Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease
    Massimo Breccia
    Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161 Rome, Italy
    Expert Opin Pharmacother 13:1031-43. 2012
    ..The results of ongoing randomized studies should better define the role of ATO in front-line therapy...
  12. ncbi Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients
    M Breccia
    Dept of Human Biotechnologies and Hematology, Roma, Italy
    Curr Cancer Drug Targets 12:391-401. 2012
    ..Longer follow-up is however needed to prove the advantages of faster and deeper responses in terms of disease progression compared to imatinib...
  13. ncbi Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Blood 119:49-54. 2012
    ..99, in overweight/obese vs under/normal weight patients, P = .049). An increased BMI at diagnosis is associated with a higher risk of developing differentiation syndrome and disease relapse in APL patients treated with AIDA protocols...
  14. ncbi Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Cancer Chemother Pharmacol 63:1161-3. 2009
    ..We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose...
  15. ncbi Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 33:645-8. 2009
    ....
  16. ncbi Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Cancer Chemother Pharmacol 64:195-7. 2009
    ....
  17. ncbi Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, 00161 Rome, Italy
    Hematol Oncol 27:148-53. 2009
    ..001). Comorbidities are independent factors that influence survival. Application of CCI and Dombret score may help to better identify patients at diagnosis who can benefit from intensive chemotherapy...
  18. ncbi Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem
    Massimo Breccia
    Department of Human Biotechnology and Hematology, Via Benevento 6, 00161 Roma, Italy
    Cardiovasc Hematol Disord Drug Targets 9:21-8. 2009
    ..This review will discuss the underlying mechanisms of imatinib-resistance and new strategies to avoid and overcome this phenomenon...
  19. ncbi Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Lymphoma 49:1292-6. 2008
    ..Furthermore, we believe this is a further evidence for the arbitrary nature of current classification systems, which definitely exclude CMML from myelodysplastic syndromes...
  20. ncbi Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Acta Haematol 118:162-4. 2007
  21. ncbi Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Lymphoma 49:2328-32. 2008
    ....
  22. ncbi Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 32:177-80. 2008
    ..The few previous observations from literature are also reviewed...
  23. ncbi Cocaine abuse may influence the response to imatinib in CML patients
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Haematologica 92:e41-2. 2007
  24. ncbi Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Acta Haematol 117:221-5. 2007
    ..In conclusion, the RAEB-t entity according to the FAB criteria, although including heterogeneous clinical patient subsets, should more likely be considered as an advanced stage of MDS, rather than a true acute myeloid leukaemia...
  25. ncbi Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Acta Haematol 116:211-2. 2006
  26. ncbi The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 33:871-5. 2009
    ..The aim of this review is to report the changes caused by imatinib on glucose, lypidic and bone metabolism...
  27. ncbi Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy
    Leuk Res 34:143-7. 2010
    ..Second-generation TKIs given before allo-HSCT do not negatively affect transplant engraftment and response rate, nor increases transplant-related toxicity...
  28. ncbi Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib
    Massimo Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Roma, Italy
    Haematologica 96:1457-61. 2011
    ....
  29. ncbi 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 35:1409-11. 2011
    ..We reported here 4 patients treated with azacitidine for therapy related dysplasia after chemotherapy for non-Hodgkin lymphoma...
  30. ncbi Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
    Massimo Breccia
    Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161 Roma, Rome, Italy
    Expert Opin Biol Ther 11:225-34. 2011
    ..EXPERT OPINION: GO has proven effective and relatively safe as a single agent in advanced APL. In combinations with ATRA and/or ATO, GO may substitute for conventional chemotherapy of APL, particularly in unfit patients...
  31. ncbi Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy
    Cancer Lett 300:115-21. 2011
    ....
  32. ncbi NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia
    Massimo Breccia
    Sapienza University, Department of Human Biotechnologies and Hematology, Rome, Italy
    Expert Opin Ther Targets 14:1157-76. 2010
    ..There are several reports that inhibition of NF-κB as a therapeutic target may have a role in tumour cell death or growth inhibition...
  33. ncbi Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development
    Massimo Breccia
    Sapienza University, Department of Cellular Biotechnologies and Hematology, Via Benevento 6, 00161, Rome, Italy
    Expert Opin Drug Saf 9:713-21. 2010
    ..Changing the dasatinib regimen from 70 mg twice daily to 100 mg once daily reduces the risk of pleural effusions...
  34. ncbi The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, Sapienza University, Rome, Italy
    Crit Rev Oncol Hematol 79:135-43. 2011
    ....
  35. ncbi Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Leuk Res 35:159-62. 2011
    ..01 to 0.004). In conclusion, assessment of comorbidities at diagnosis in MDS patients may improve the ability of therapeutic decisions...
  36. ncbi Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients
    Massimo Breccia
    Department of Biotechnologies and Hematology, Via Benevento 6, 00161 Rome, Italy
    Leuk Lymphoma 51:783-8. 2010
    ....
  37. ncbi Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia
    Massimo Breccia
    Department of Biotechnologies and Hematology, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 34:129-34. 2010
    ..The aim of this review is to evaluate the pharmacology, pharmacokinetic and pharmacodynamic properties of the drug and the recent results of clinical trials performed in patients with CML and Ph+ acute lymphoblastic leukemia (ALL)...
  38. ncbi Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Hematol Oncol 28:89-92. 2010
    ..5%). CMR and major molecular response (MMR) were detected in 20 and 22% of patients, respectively. Low dose imatinib appears effective in patients with intolerance to standard dose, even though long-term effects remain to be established...
  39. ncbi Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Curr Drug Targets 10:530-6. 2009
    ..We here review the development of nilotinib and the efficacy data in phase II and front-line trials...
  40. ncbi Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon
    M Breccia
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 30:1577-9. 2006
    ....
  41. ncbi Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Eur J Haematol 75:396-400. 2005
    ..Furthermore, we suggest the need of routine screening for thrombophilic state in young women affected by PV...
  42. ncbi Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation
    Massimo Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 29:33-9. 2005
    ....
  43. ncbi The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose
    Massimo Breccia
    Sapienza University, Department of Human Biotechnologies and Hematology, Via Benevento 6, Rome, Italy
    Expert Opin Pharmacother 12:2075-87. 2011
    ..In newly diagnosed patients, high-dose imatinib produced increased response rates, which in some instances were not significant compared with standard dose...
  44. ncbi Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Eur J Haematol 74:121-3. 2005
    ..We report on our experience relating to dermatological toxicities in imatinib treated CML patients showing a spectrum of skin reactions ranging from rashes to cutaneous carcinoma...
  45. ncbi Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Haematologica 89:ECR11. 2004
  46. ncbi Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, La Sapienza University, Rome, Italy
    Leuk Res 28:1165-9. 2004
    ....
  47. ncbi Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Eur J Haematol 73:304-6. 2004
    ..We describe the first case of PCH presented as a late manifestation of advanced myelofibrosis associated with antiphospholipid syndrome, that promptly responded to high dosage of prednisone...
  48. ncbi Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Haematologica 90:ECR21. 2005
  49. ncbi Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Haematologica 89:ECR20. 2004
  50. ncbi Acute myeloid leukemia secondary to a myelodysplastic syndrome with t(3;3) (q21;q26) in an HIV patient treated with chemotherapy and highly active antiretroviral therapy
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Acta Haematol 111:160-2. 2004
    ..The association of chemotherapy with HAART appeared to be feasible and tolerable and could be suggested as a choice treatment in this peculiar subset of HIV/AML patients...
  51. ncbi Myelodysplastic syndromes in patients under 50 years old: a single institution experience
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 29:749-54. 2005
    ..001) and high risk by IPSS score (p = 0.0003) were found to be predictive for a higher risk of transformation to AML. Presenting features in young MDS patients may identify subjects at higher risk of unfavourable outcome...
  52. ncbi Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy
    Giuliana Alimena
    Department of Cellular Biotechnology andHematology, University La Sapienza, Rome, Italy
    Cancer 107:1008-13. 2006
    ..In these patients, the occurrence of blastic crisis (BC) is rare, and its clinical biologic characteristics are not well known...
  53. ncbi Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes
    Giuliana Alimena
    Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 35:504-7. 2011
    ..In conclusion, bortezomib used alone in MDS shows modest hematologic efficacy but appears to affect the WT1 gene expression, which is typically increased in these diseases...
  54. ncbi "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia
    Roberto Latagliata
    Department of Cellular Biotechnology and Hematology, University La Sapienza of Rome, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 34:1472-5. 2010
    ..To overcome this problem, future trials concerning best dosage in this subset of patients could be useful...
  55. ncbi Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 32:353-5. 2008
    ..Therapy was well tolerated and the patient is presently alive in complete remission of either NHL and CML. We also reviewed the literature relating the uncommon association of these two unrelated diseases...
  56. ncbi Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Via Benevento 6, Rome, Italy
    Eur J Haematol 68:1-3. 2002
    ..We discuss possible pathogenetic mechanisms and suggest the use of nonalkylating drugs, such as fludarabine, for the treatment of this rare association of malignancies usually characterized by a very poor response to therapy...
  57. ncbi Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?
    Massimo Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Via Benevento 6, Rome, Italy
    Br J Haematol 118:438-41. 2002
    ..The possible role of chromosome 3q26 abnormalities in determining this peculiar clinical-biological association is emphasized...
  58. ncbi Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate
    Giuliana Alimena
    Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 32:255-61. 2008
    ....
  59. ncbi GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors
    Roberto Latagliata
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Roma, Italy
    Br J Haematol 154:564-8. 2011
    ..However, considering the recent availability of effective new agents, a less aggressive approach should be tested in this setting...
  60. ncbi Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy
    Massimo Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, , Roma, Italy
    Haematologica 89:29-33. 2004
    ..Their outcome suggests the need for early therapeutic intervention with aggressive treatment prior to the occurrence of hematologic relapse...
  61. ncbi Late relapses in acute promyelocytic leukaemia
    Roberto Latagliata
    Dipartimento di Biotecnologie Umane e Ematologia, Universita La Sapienza, Roma, Italia
    Acta Haematol 117:106-8. 2007
    ..In conclusion, a late relapse occurred in a sizeable fraction of acute promyelocytic leukaemia patients: the high rate of ear involvement might be explained considering the ear as a 'disease sanctuary'...
  62. ncbi Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience
    Claudio Cartoni
    Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, University Sapienza, Rome, Italy
    Leuk Lymphoma 50:387-91. 2009
    ..In this group of patients, bleeding was a relevant clinical problem However, by implementing a domiciliary palliative care program, home management of hemorrhages proved to be a safe and effective choice...
  63. ncbi Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia
    Roberto Latagliata
    Department of Cellular Biotechnology and Hematology, La Sapienza University, Rome, Italy
    Acta Haematol 129:126-34. 2013
    ..To address the incidence and the prognostic role of a very early standard complete cytogenetic response (CCyR) or all Ph- metaphases (MET-, when <20 cells were evaluable)...
  64. ncbi Ocular side effects in chronic myeloid leukemia patients treated with imatinib
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 32:1022-5. 2008
    ..We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma...
  65. ncbi Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
    Francesco Lo-Coco
    Department of Biopathology, University Tor Vergata of Rome, Via Montpellier 1, Rome, Italy
    Blood 116:3171-9. 2010
    ..Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group...
  66. ncbi Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita Tor Vergata, Rome, Italy
    Blood 104:1995-9. 2004
    ..These data indicate that GO is highly effective as a single treatment for patients with molecularly relapsed APL including those with very advanced disease...
  67. ncbi Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib
    Roberto Latagliata
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Leuk Res 35:1164-9. 2011
    ..Cumulative OS at 24 and 48 months were 93.1% (95% CI 88.4-97.8) and 84.2% (95% CI 74.6-93.7). Dasatinib, at the recommended dose of 100mg/day, is effective and safe also in unselected elderly subjects...
  68. ncbi Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment
    Roberto Latagliata
    Dipartimento di Biotecnologie Umane ed Ematologia, Universita La Sapienza di Roma, Via Benevento 6 00161, Rome, Italy
    Leuk Res 29:287-91. 2005
    ..Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients...
  69. ncbi Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase
    Massimo Breccia
    Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
    Mediterr J Hematol Infect Dis 3:e2011021. 2011
    ..Imatinib has become first line therapy in chronic myeloid leukemia patients. Little is known about the infective consequences during the treatment with this drug in large series of chronic phase patients...
  70. ncbi Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem
    Roberto Latagliata
    Department of Human Biotechnologies and Hematology, University La Sapienza of Rome, Cattedra di Ematologia, Via Benevento 6 00161, Rome, Italy
    Blood 99:822-4. 2002
    ....
  71. ncbi AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation
    Massimo Breccia
    Dept. of Human Biotechnology and Hematology of the University La Sapienza of Roma, Via Benevento 6, 00161 Roma, Italy
    Haematologica 87:ELT12. 2002
  72. ncbi Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia
    Corrado Girmenia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza, Rome, Italy
    Ann Hematol 86:263-70. 2007
    ..As for low-risk patients, hospitalization at least in the first days of fever is required. Cefixime could be included among the oral antibacterial drugs to be used in the outpatient treatment of adult patients with febrile neutropenia...
  73. ncbi Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results
    Roberto Latagliata
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Int J Hematol 90:486-91. 2009
    ..This scoring system appears effective to discriminate a different risk of thrombotic events, and could be useful to decide when a PLT-lowering therapy needs to be started...
  74. ncbi Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features
    Anna Guarini
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Sezione di Ematologia, Via Benevento 6, 00161 Rome, Italy
    Blood 102:1035-41. 2003
    ..At a time when aggressive therapeutic strategies are always more frequently used in the management of CLL, the distinctive features of patients with long-lived stable disease should be prospectively identified at presentation...
  75. ncbi Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes
    Massimo Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy
    Leuk Res 30:178-82. 2006
    ..Our study provides evidence that WHO classification may have prognostic impact on MDS subgroups which are usually categorized by FAB as having a favourable outcome...
  76. ncbi Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
    Roberto Latagliata
    Ematologia, Universita La Sapienza, Rome, Italy
    Br J Haematol 143:681-9. 2008
    ..DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses...
  77. ncbi Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies
    Claudio Cartoni
    Division of Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, University La Sapienza of Rome, Italy
    Haematologica 92:666-73. 2007
    ..For some categories of patients, costs of HC are lower than those of hospitalization, although higher than the current national fares for HC programs...
  78. ncbi Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
    N I Noguera
    Department of Cellular Biotechnologies and Hematology, University La Sapienza of Roma, Italy
    Leukemia 16:2185-9. 2002
    ..Our results indicate that FLT3 alterations are associated in APL with more aggressive clinical features and suggest that these lesions may not play a major role in leukemia progression...
  79. ncbi Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center
    Corrado Girmenia
    Dipartimento di Ematologia, Oncologia, Anatomia Patologica e Medicina Rigenerative, Azienda Policlinico Umberto I, Sapienza Universita di Roma, Roma, Italia
    Acta Haematol 126:1-7. 2011
    ..The viral disease had a generally favorable outcome despite the high frequency of pulmonary involvement. A prompt clinical evaluation with an early antiviral and supportive therapy may have played a beneficial role in the outcome...
  80. ncbi The importance of molecular monitoring in acute promyelocytic leukaemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, Universita di Roma Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Best Pract Res Clin Haematol 16:503-20. 2003
    ..The introduction of quantitative PCR through automated technologies is likely to further improve standardization of the method and comparison of results obtained in the context of large clinical trials...
  81. ncbi Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia
    Francesco Lo-Coco
    Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy
    Best Pract Res Clin Haematol 16:653-70. 2003
    ..Further, we discuss briefly the clinical utility of detecting these alterations for prognostic assessment and evaluation of response to treatment...
  82. ncbi Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen
    C Girmenia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy
    Leukemia 17:925-30. 2003
    ..These results indicate that a particular pattern of infections is observed in APL patients receiving ATRA plus anthracycline-based chemotherapy and that these appear to be effectively counteracted by standard management...
  83. ncbi Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation
    Massimo Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Via Benevento 6, Rome, Italy
    Eur J Haematol 70:190-2. 2003
    ..We highlight the importance of an accurate immunohistochemical diagnosis and of an early and intensive acute myeloid leukemia-like treatment for these cases representing an uncommon and aggressive form of acute leukemia...
  84. ncbi Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes
    I Casorelli
    Section of Experimental Carcinogenesis, Department of Environment and Primary Prevention, Istituto Superiore di Sanit, Rome, Italy
    Leukemia 20:1978-88. 2006
    ..Although both secondary and de novo APL were characterized by a strong homogeneity in expression profiling, we identified a small set of differentially expressed genes that discriminate sAPL from de novo cases...
  85. ncbi Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission
    A Guarini
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy
    Br J Haematol 113:136-42. 2001
    ..The design of therapeutic strategies aimed at stimulating the host immune compartment finds a further rationale for CML patients responsive to treatment with both IFN alpha and hydroxyurea...
  86. ncbi Melphalan treatment in patients with myelofibrosis with myeloid metaplasia
    M C Petti
    Ematologia, Istituto Regina Elena, Rome, Italy
    Br J Haematol 116:576-81. 2002
    ..4) and not achieving any type of response, either partial or complete (HR = 3.9). In conclusion, Melphalan could be a promising first-line option for MMM patients with clinical or haematological symptoms requiring treatment...
  87. ncbi Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine
    M Breccia
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy
    Ann Hematol 80:614-6. 2001
    ..This process was associated with sepsis and resolved with conservative therapy of the underlying condition, using granulocyte colony-stimulating factor and intravenous neostigmine. We discuss the management of this rare syndrome...
  88. ncbi Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal
    M Breccia
    Department of Cellular Biotechnology and Hematology, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Leuk Res 33:391-4. 2009
    ..001). WHO classification provides valuable prognostic information for RAEB patient population, and can identify those subjects with more unfavourable prognosis who should be offered alternative therapeutic strategies...
  89. ncbi Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon
    R Latagliata
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza di Roma, Ematologia, Ospedale S Giovanni, Roma, Ematologia, Istituto Regina Elena, Roma, Italy
    Ann Oncol 17:281-5. 2006
    ..About 50% of the patients are not eligible for aggressive chemotherapy (CT) and are only managed with conservative approaches. Results in this subset of patients have not been reported so far...
  90. ncbi Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission
    Giovanni F Torelli
    Department of Cellular Biotechnologies and Haematology, University of Rome La Sapienza, Rome, Italy
    Br J Haematol 116:299-307. 2002
    ....
  91. ncbi Pregnancy in patients with myelodysplastic syndromes (MDS)
    P Volpicelli
    Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza di Roma, Italy
    Leuk Res 32:1605-7. 2008
    ..In conclusion, selected females with low-risk MDS could not be discouraged to have full term pregnancies...
  92. ncbi Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated 'sanctuary'?
    M Breccia
    Department of Cellular Biotechnologies, University La Sapienza, Rome, Italy
    Leukemia 16:1127-30. 2002
    ..We suggest that the ear might represent a specific sanctuary for disease involvement in APL...
  93. ncbi Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event
    M C Petti
    Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Haematologica 86:1277-80. 2001
    ..It should be kept in mind in the evaluation of experimental treatments for MDS in which very low rates of complete responses are expected...
  94. ncbi Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid
    Vincenza Martini
    Ann Hematol 86:295-7. 2007
  95. ncbi Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias
    Maria José Carnicer
    Department of Biopathology and Department of Laboratory Medicine PTV, University of Rome Tor Vergata, Italy
    Clin Chim Acta 365:342-5. 2006
    ..The regulation of gamma-glutamylcysteine synthetase (gamma-GCS) is one of the major determinants of GSH homeostasis. The aim of our study was to investigate gamma-GCS gene expression in patients affected by acute myeloid leukemia (AML)...
  96. ncbi Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?
    Massimo Breccia
    Eur J Haematol 75:89-90. 2005
  97. ncbi Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases
    Massimo Breccia
    Leuk Res 32:519-20. 2008
  98. ncbi Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    , University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..0005 and as a 3-log reduction from median baseline value) already at the time of first achieving a CCgR have significantly longer cytogenetic remission durations than those without this magnitude of molecular response (P < 0.05)...
  99. ncbi Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia
    Ida Carmosino
    Haematologica 89:615-7. 2004
    ..We suggest that ATO may be effective also in advanced APL, but given the short CR, it seems indicated only in patients eligible for transplant procedures...
  100. ncbi Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution
    Massimo Breccia
    Haematologica 89:866-8. 2004
    ....
  101. ncbi Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib
    Massimo Breccia
    Eur J Haematol 74:89-90. 2005